טוען...
CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV
INTRODUCTION: The chemokine receptor CCR5 has garnered significant attention in recent years as a target to treat HIV infection largely due to the approval and success of the drug Maraviroc. The side effects and inefficiencies with other first generation agents led to failed clinical trials, prompti...
שמור ב:
| הוצא לאור ב: | Expert Opin Investig Drugs |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5776690/ https://ncbi.nlm.nih.gov/pubmed/27791451 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/13543784.2016.1254615 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|